Table 2.
Characteristics of SOT recipients with versus without SARS-CoV-2 infection.
| No infection | Infection | P-value | |
|---|---|---|---|
| Number of patients | 1710 | 247 | |
| Type of transplant | |||
| Only kidney | 507 (29.68%) | 59 (23.87%) | 0.447 |
| Only heart | 279 (16.31%) | 39 (15.8%) | |
| Only liver | 258 (15.08%) | 68 (27.57%) | |
| Only lung | 506 (29.59%) | 60 (24.29%) | |
| Multi-organ* | 160 (9.33%) | 21 (8.66%) | |
| Male | 1011 (59.10%) | 146 (59.27%) | 0.781 |
| Age (years) | 58.2 (13.48) | 57.8 (15.36) | 0.041 |
| BMI ≥ 30 | 260 (15.21%) | 45 (18.06%) | 0.754 |
| Medically treated hypertension | 1401 (81.95%) | 191 (77.17%) | 0.038 |
| Medically treated diabetes | 476 (27.81%) | 87 (35.38%) | 0.013 |
| Chronic kidney disease | 887 (51.86%) | 110 (44.62%) | 0.194 |
| Chronic heart disease | 253 (14.80%) | 48 (19.43%) | 0.347 |
| Chronic lung disease | 103 (6.02%) | 28 (11.38%) | < 0.001 |
| Chronic liver disease | 24 (1.40%) | 6 (2.43%) | 0.107 |
| Chronic neurological disease | 108 (6.30%) | 18 (7.37%) | 0.556 |
| Known HIV | 4 (0.23%) | 0 (0.00%) | NA |
| Current or past malignancy (solid organ or hematological; excl. skin tumors) | 122 (7.12%) | 13 (5.34%) | 0.230 |
| Chemo-/immunotherapy against malignancy in 2020 | 9 (0.50%) | 0 (0.00%) | 0.972 |
| Tacrolimus | 1483 (86.75%) | 216 (87.29%) | 0.696 |
| Tacrolimus off-peak level (µg/L) | 6.0 (3.23) | 5.7 (3.33) | 0.142 |
| Cyclosporine | 186 (10.85%) | 25 (10.28%) | 0.380 |
| Cyclosporine off-peak level (µg/L) | 13.0 (41.87) | 11.6 (40.82) | 0.387 |
| Mycophenolate | 1106 (64.69%) | 140 (56.88%) | 0.055 |
| Mycophenolate daily dose (mg) | 651.2 (636.95) | 566.7 (700.07) | 0.002 |
| Azathioprine | 199 (11.62%) | 25 (10.24%) | 0.727 |
| Azathioprine daily dose (mg) | 75 (4.36%) | 8 (3.04%) | 0.770 |
| Corticosteroids (methylprednisone) | 997 (58.30%) | 123 (49.64%) | 0.543 |
| Corticosteroids daily dose (4 mg) | 699 (40.85%) | 85 (34.53%) | 0.829 |
| Everolimus | 113 (6.60%) | 16 (6.56%) | 0.724 |
| Everolimus peak-off level (µg/L) | 0.3 (1.09) | 0.3 (1.07) | 0.572 |
| Number of housemates | |||
| 0 | 225 (13.14%) | 32 (13.04%) | 0.953 |
| 1 | 863 (50.48%) | 125 (50.57%) | |
| > 1 | 622 (36.38%) | 90 (36.40%) | |
| Covid suspicion among housemates | 50 (2.94%) | 44 (17.81%) | < 0.001 |
| Been within 1.5 m of confirmed Covid patient | 85 (4.98%) | 65 (26.44%) | < 0.001 |
| Always compliant with COVID rules | 1242 (72.63%) | 167 (67.53%) | 0.551 |
| Housemates (+ 16y) were always compliant with COVID rules | 905 (52.94%) | 127 (51.46%) | 0.929 |
| Patient never bought food during lock-down | 718 (41.99%) | 114 (46.23%) | 0.057 |
| Patient always wears mouth mask if social distance of 1.5 m cannot be kept | 1528 (89.33%) | 211 (85.55%) | 0.181 |
| Spent at least 1 night abroad since February 4th 2020 | 261 (15.25%) | 44 (17.94%) | 0.147 |
SARS-CoV-2 infection was defined as positive SARS-CoV-2 PCR and/or positive SARS-CoV-2 IgG antibody titre.
P-values are obtained from Cox PH model with missing data accounted for by performing 10 multiple imputations.
*The multi-organ transplant group also contains 1 single pancreas and 2 only intestine transplant recipients.
Significant values are given in bold.